BIRB796,the Inhibitor of p38 Mitogen-Activated Protein Kinase,Enhances the Efficacy of Chemotherapeu

• 作 者: DanHe;Guo-qingZhang;
• 机 构: Department of Thoracic Surgery,Affiliated Tumor Hospital Xinjiang Medical University,Urumuqi 830011,
• 出 处: 2012医学科学前沿暨第二届个体化治疗与抗肿瘤药物研究新趋向研讨会
• 发表日期: 2012年期

　　ATP-binding-cassette family membrane proteins play an important role in multidrug resistance.In this study,we investigated the possible interaction of BIRB796,an orally active inhibitor of p38 mitogen-activated protein kinase,with ABCB1,ABCG2 and ABCC1.Our results showed that BIRB796 could reverse ABCB1-mediated MDR to chemotherapeutic agents such as doxorubicin and paclitaxel in both the drug selected and transfected ABCB1-overexpressing cells,but had no enhancement effect on their parental sensitive cells and ABCC1 and ABCG2 overexpression cells.